IngentaConnect Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), ...

Abstract:

Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1 kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that chelates Yttrium or Indium and is directed against the CD 20 molecules of B lymphocytes. Phase I studies have determined the optimal dose of pretreatment rituximab to be 250 mg / m2 seven days prior and immediately prior to the administration of Zevalin. Phase I / II data have determined the dose of 0.4 mCi / kg to be the maximum tolerated dose (MTD) for patients with platelet counts > 150,000 and < 25percent bone marrow involvement with NHL. The dose of 0.3 mCi / kg is the MTD in patients with platelet counts between 100,000-149,000. Toxicity is primarily hematologic, transient, and reversible. Dosimetry has been completed using 111In-2B8. Results to date demonstrate that, at the above doses, no patients exceeded the protocol-prescribed organ maximum dose of 2,000 cGy or red marrow maximum dose of 300 cGy. Therefore, future use will not require pretreatment dosimetry. Zevalin contains a pure beta-emitting isotope no protective patient or staff isolation procedures are required. A randomized Phase III trial has been completed, comparing Zevalin with a standard dose of rituximab (375 mg / m2 q week for four weeks) in patients with relapsed indolent or follicular transformed NHL. The overall response rate (ORR) was 80 percent in the Zevalin arm compared to 56 percent (p = 0.002) in the rituximab arm. The CR was 30 percent vs 16 percent (p=0.04). A nonrandomized trial in patients refractory to rituximab demonstrated an ORR of 74 percent and a CR rate of 15 percent. A Phase II study of a reduced dose of Zevalin in patients with mild thrombocytopenia demonstrated an ORR of 67 percent and a 33 percent CR rate. Zevalin is safe and effective in patients with relapsed or refractory NHL, even in patients refractory to prior rituximab therapy.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy

Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma